Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Effectiveness of reconsolidation therapy with propranolol to treat adjustment disorder (AD) stemming from romantic betrayal: A 2-year follow-up

FY 2018-19

Summary
Considering that romantic betrayal events can result in the development of an adjustment disorder (AD) in the betrayed partner, effective therapies with long-lasting benefits are needed for this population. The aim of the current study is to provide a follow-up assessment of romantically betrayed participants from a previous clinical trial, who received a trauma-focused intervention known as reconsolidation therapy to treat an AD. Research demonstrates that propranolol, a beta-blocker commonly used to treat hypertension, can dampen the emotional intensity of a memory when taken before memory recall. Propranolol does so by effectively disrupting memory reconsolidation, a process by which memories are reinforced. The previous study found that compared to participants on the wait-list, 4-6 sessions of reconsolidation therapy reduced stressor-related symptoms, and symptoms of depression and anxiety. Still, little is known of the long-term effectiveness of reconsolidation therapy. The current study will therefore examine whether reconsolidation therapy shows long-term benefits for romantically betrayed individuals with an AD. Compared to participants who did not complete the treatment, those who completed the treatment are expected to show a continued reduction in stressor-related, depression, and anxiety symptoms, 2-years following treatment. These findings may have important implications for understanding romantic betrayal as a stressful event leading to the development of AD and may further our understanding of effective treatments for this population.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
406514
Name
Pigeon Sereena
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Effectiveness of reconsolidation therapy with propranolol to treat adjustment disorder (AD) stemming from romantic betrayal: A 2-year follow-up
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adjustment Disorder; Follow-Up; Reconsolidation Therapy; Romantic Betrayal
Abstract
Considering that romantic betrayal events can result in the development of an adjustment disorder (AD) in the betrayed partner, effective therapies with long-lasting benefits are needed for this population. The aim of the current study is to provide a follow-up assessment of romantically betrayed participants from a previous clinical trial, who received a trauma-focused intervention known as reconsolidation therapy to treat an AD. Research demonstrates that propranolol, a beta-blocker commonly used to treat hypertension, can dampen the emotional intensity of a memory when taken before memory recall. Propranolol does so by effectively disrupting memory reconsolidation, a process by which memories are reinforced. The previous study found that compared to participants on the wait-list, 4-6 sessions of reconsolidation therapy reduced stressor-related symptoms, and symptoms of depression and anxiety. Still, little is known of the long-term effectiveness of reconsolidation therapy. The current study will therefore examine whether reconsolidation therapy shows long-term benefits for romantically betrayed individuals with an AD. Compared to participants who did not complete the treatment, those who completed the treatment are expected to show a continued reduction in stressor-related, depression, and anxiety symptoms, 2-years following treatment. These findings may have important implications for understanding romantic betrayal as a stressful event leading to the development of AD and may further our understanding of effective treatments for this population.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Pigeon, Sereena
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~